

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

## Tables:

	<b>MCF7</b>	<b>U251</b>	<b>Astrocytes</b>	<b>Monocytes</b>	<b>B cells</b>	<b>HeLa</b>
Genes that respond to hypoxia	830	1702	1371	486	1920	2119
Genes that respond to hypoxia in which a HIF binding site was identified	278 (33%)	546 (32%)	380 (28%)	159 (33%)	534 (28%)	555 (26%)
Known target genes that respond to hypoxia	35	31	20	22	32	27
Known target genes recovery	19 (54%)	17 (55%)	8 (40%)	11 (50%)	13 (41%)	10 (37%)

Table 1. Transcriptional response to hypoxia across six different cell types as determined by microarrays.

Source	Description	Number of genes	Previously Validated HIF-1 Targets		Novel HIF-1 Targets
			p-value	Gene symbols	
Protein domains	IPR005123; 2-oxoglutarate (2OG) and Fe(II)-dependent oxygenase	6/19	2.E-07	P4HA2, EGLN3, EGLN1, P4HA1, PH-4	PLOD1
GSEA	Poor prognosis marker genes in Breast Cancer	13/104	1.E-07	CA9, CP, PGK1, EGLN1, TFRC, VEGFA, NDRG1, ADM, BNIP3	TMEFF1, IVNS1ABP, TMEM45A, RRAGD
KEGG	Arginine and proline metabolism	6/35	4.E-05	P4HA2, NOS3, P4HA1, NOS2A	EPRS, ALDH4A1
Reactome	Platelet Activation	7/86	1.E-02	PDGFA, TGFB3, FN1, VEGFA, ALDOA, SERPINE1	ARHGEF1
TargetScan	miR-1/206	23/583	3.E-03	PDGFA, NAMPT, HSP90B1, MET, ETS1, VEGFA, EDN1, CITED2, STC2	RNF165, GRK6, SLC7A6, PTPLAD1, ASPH, MYLK, RSBN1, SLC31A1, EVI1, PGAM1, SOX6, BTAF1, MXD1, GLCCI1
Protein interactions	PCAF	10/106	9.E-05	ENO1, NR4A1, PFKL, PGK1	RARA, CCNB1, SSRP1, RBPJ, EVI1, BTAF1

Table 2. Selected examples of functional enrichment of 101 previously validated HIF-1 targets and mapping of novel targets to these categories. The number of genes reflect the total number of known and predicted targets within the functional group. P-values for enrichment of validated HIF-1 targets were obtained using the hypergeometric distribution as described in Materials and Methods.